glp 1 shortage fda What Changed? The FDA's Clarification on Compounded GLP-1 Drugs fda semaglutide shortage status january

R., Wefers, J., & Meier, J

Semaglutide 2.4mg (GLP-1 Agonist): Proven GLP-1 effects (appetite suppression, gastric emptying) Already FDA-approved as Wegovy Established safety profile Cagrilintide 2.4mg (Amylin Analog): Mimics amylin, a hormone co-secreted with insulin Slows gastric emptying through different pathway than GLP-1 Reduces appetite through hindbrain (not hypothalamus) Improves postprandial glucose The Advantage: Leverages proven semaglutide efficacy and safety, adds complementary amylin effects

However, the full results of the treatment will become more pronounced in the following weeks.Its important to note that the number of sessions required may vary depending on the specific area being treated and the amount of fat involved

The solution should be completely clear and colorless